Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06433947
- Locations
- ๐บ๐ธ
Emory Winchip Cancer Center, Atlanta, Georgia, United States
๐บ๐ธBanner MD Anderson, Gilbert, Arizona, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 19
- Registration Number
- NCT04556617
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
๐ฌ๐งSarah Cannon Research Institute, London, United Kingdom
๐บ๐ธCarolina Urologic Research Center, Myrtle Beach, South Carolina, United States
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 37
- Registration Number
- NCT04493619
- Locations
- ๐บ๐ธ
University of Virginia Health Systems, Charlottesville, Virginia, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธUniversity of Oklahoma - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 22
- Registration Number
- NCT03787498
- Locations
- ๐บ๐ธ
Northside Hospital, Atlanta, Georgia, United States
๐บ๐ธSidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
๐บ๐ธNewYork-Presbyterian / Weill Cornell Medical Center, New York, New York, United States
A Study of PLX2853 in Advanced Malignancies.
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 49
- Registration Number
- NCT03297424
- Locations
- ๐บ๐ธ
Sylvester Comprehensive Cancer Center / University of Miami Miller School of Medicine, Miami, Florida, United States
๐บ๐ธSouth Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
๐บ๐ธColumbia University Medical Center, New York, New York, United States